Biopharmaceutical company Roivant (Nasdaq:ROIV) said on Friday that it will host a live conference call and webcast on Friday, 6 February 2026, to report its financial results for the second quarter ended 31 December 2026, and provide a business update.
Details of the presentation and webcast will be available under 'Events & Presentations' in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.
The archived webcast will be available on Roivant's website after the conference call.
Roivant's pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease.
Sanofi's rilzabrutinib receives orphan drug designation in Japan for IgG4-related disease
Johnson & Johnson submits sBLA to FDA for first-ever treatment for wAIHA
Genentech reports positive Phase III MAJESTYdata for Gazyva in primary membranous nephropathy
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
Amgen wins European approval for Uplizna in generalised myasthenia gravis
Akeso's AK139 Phase II clinical trials approved in China
Eli Lilly signs definitive agreement to acquire Orna Therapeutics
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals